Semaglutide is the active ingredient in several products with different approved uses and instructions. Wegovy provides weight-management options.
Semaglutide is the active ingredient in several products with different approved uses and instructions. Wegovy provides weight-management options. Ozempic injection and Ozempic tablets/Rybelsus are diabetes products. Choosing a product requires more than choosing the ingredient.
Semaglutide activates the GLP-1 receptor. It affects appetite, slows stomach emptying, and helps glucose regulation. The brand, route, dose, and diagnosis determine the approved use. Tablets and injections cannot be exchanged milligram for milligram.
Wegovy injection includes adults with obesity, selected adults with overweight, and children 12 and older with obesity. Wegovy tablets have adult indications. Ozempic products treat adults with type 2 diabetes, with additional product-specific indications. Compounded products are not FDA-approved equivalents.
Review whether the goal is diabetes, weight, cardiovascular risk, or qualifying MASH care. Select the exact approved product, review medical risks and insurance requirements, and teach its use. Set a nutrition and monitoring plan. A switch or restart after an interruption needs prescriber review.
Bring your weight and treatment history, medicines and supplements, relevant glucose, kidney, and lipid results, and the exact product you have used before. Mention previous side effects, eye disease, eating difficulties, and pregnancy plans. If insurance denied treatment, bring the denial and plan details.
Review a personal or family history of medullary thyroid cancer, MEN 2, severe stomach-emptying problems, pancreatitis, gallbladder disease, allergies, and pregnancy plans before treatment. Nausea, vomiting, constipation, or diarrhea can occur. Persistent severe abdominal pain or inability to keep fluids down needs emergency department assessment now. Call 911 for breathing difficulty, a severe allergic reaction, loss of consciousness or unsafe travel. Tell the anesthesia team about treatment before a procedure. Do not combine GLP-1 medicines or change the dose yourself. For weight treatment, stop semaglutide at least two months before a planned pregnancy with prescriber guidance. Do not buy “research use only” products or assume compounded concentrations and syringe units are interchangeable.
Review weight trend, appetite, food and fluid intake, bowel symptoms, and treatment tolerability. Check glucose and adjust other diabetes medicines with the prescriber when relevant. Agree on how to contact the team between visits and what to do if a refill is delayed. Continued treatment depends on benefit, safety, access, and your goals.
Confirm the exact service, clinician, formulation, appointment, and refill route before booking. The evaluation, tests, medicine, administration, and follow-up may have separate costs and benefits. Ask for current estimates and required records. An FDA-approved drug or a clinic address does not establish pharmacy stock, onsite treatment, coverage, or a prescription. If access changes, contact the treating team before interrupting treatment.
Diabetes is not required for every approved obesity medicine, but suitability depends on the exact product and its indication. Compounding does not create a broader approved indication or make a product equivalent to Wegovy. Review obesity criteria, medical risks, and an approved option with the prescriber.
Weight treatment may continue long term when it remains useful and safe, with regular reassessment. That does not establish that a compounded product is appropriate indefinitely. Review the exact product, FDA-approved alternatives, tolerability, access and a maintenance plan with the prescriber; do not stop or restart after a gap without advice.
Weight regain can occur after semaglutide treatment stops, but the amount varies. Discuss nutrition, activity, follow-up and appropriate ongoing treatment before stopping. A compounded product’s continued availability or suitability is a separate question. If there is a gap, ask the prescriber about restarting rather than resuming the previous dose yourself.
A varied eating plan with adequate nutrients and fluids remains important. Reduced appetite can make it harder to eat enough. Compounding does not change the need for nutrition or medical review, and it does not establish FDA approval. Discuss persistent poor intake with the prescriber and dietitian.
Use the missed-dose instructions for the exact brand, formulation, and time since the scheduled dose. Do not double up, repeat an injection after vomiting, or restart a high dose after a long gap yourself. Contact the prescriber if uncertain or if refills will be delayed.
Coordination with primary care helps keep medicines, tests, metabolic health, and follow-up connected. Confirm Nao Medical’s current program requirements before booking. Ask which enrollment requirements apply to you.
